Director Leslie V. Norwalk Receives Equity Awards at Neurocrine Biosciences

This Form 4 filing discloses that Leslie V. Norwalk, a director of Neurocrine Biosciences Inc., received two equity awards on May 27, 2026. The director was granted 1,284 restricted stock units (RSUs) that will vest in full on May 27, 2027, with each RSU representing the right to receive one share of common stock upon vesting. Additionally, Norwalk received 2,624 non-qualified stock options with an exercise price of $155.83 per share, which will vest in 12 monthly installments beginning June 27, 2026, and expire on May 27, 2036. Both awards were granted at no cost to the director and represent standard equity compensation for board members. The filing was signed by Darin Lippoldt as attorney-in-fact on May 29, 2026.